| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Providing a
clear picture
Supporting patient care
At Mayo Clinic, we offer a comprehensive approach to neuro-oncology testing that focuses on the best outcomes for the patient. Our advanced genetic testing combines molecular and cytogenetic analysis to complement standard morphological and histological assessment. This maximizes the amount of available information and provides a clear picture of the diagnosis, prognosis, and treatment options.
A complete assessment
By performing immunohistochemical, molecular, and cytogenetic
analysis on all patients, our testing approach provides a more complete assessment of the patient’s diagnosis, prognosis, and therapy options.
Actionable answers
Broad molecular and cytogenetic information is needed for all
neuro-oncology patients in order to select the most appropriate treatment options, whether standard, off-label, or clinical trial.
A clear diagnosis
Understanding specific molecular markers is necessary to make a diagnosis that meets classification guidelines and can guide treatment decisions and therapeutic timelines.
Additional resources
PACE/State of CA/State of FL - This “Specialty Testing” webinar will discuss the collaborative effort which led to the discovery of Kelch like protein 11 (KLHL11) IgG as a specific biomarker of neurological autoimmunity associated testicular germ cell tumor.
The genetic variability of glioma, and its more advanced relative glioblastoma, has made genetic testing to identify biomarkers associated with prognosis and treatment effectivity an integral component of care plan development. However, the acceleration of brain tumor research and discovery translates into an ever-changing testing environment.
This "Specialty Testing" webinar will address practical aspects and pitfalls in the molecular diagnosis of brain tumors.
At Mayo Clinic, we offer a comprehensive approach to testing that focuses on the best outcomes for the patient. Our testing method combines molecular and cytogenetic analysis (in addition to a standard morphological and histological assessment) to provide a clear picture of the diagnosis, prognosis, and treatment options. This approach maximizes the amount of information available, allowing for a tailored treatment plan.
Neuro-oncology is a complex field undergoing rapid changes with the advancement and evolution of sophisticated genetic testing. Evidence continues to grow in support of broad molecular and cytogenetic analysis for patients with brain tumors.
